<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895661</url>
  </required_header>
  <id_info>
    <org_study_id>09-054</org_study_id>
    <nct_id>NCT00895661</nct_id>
  </id_info>
  <brief_title>High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas</brief_title>
  <official_title>Phase II Trial of Increased Dose Rituximab Plus Maintenance Rituximab for Initial Systemic Treatment of Indolent B-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to see if increased doses of rituximab are safe and
      effective for the initial treatment of indolent B-cell lymphomas. Rituximab (Rituxan) is a
      type of drug called an &quot;antibody&quot; that specifically targets B-cell lymphoma cells, and is
      approved by the FDA for the treatment of indolent B-cell non-hodgkin lymphomas and certain
      other types of non-hodgkin lymphomas. Standard doses currently used may not be achieving
      maximal efficacy. Higher doses have been shown to be safe in other clinical trials, and may
      offer superior efficacy to the current standard dose. This trial also employs intermittent
      maintenance doses of rituximab at the standard dose, which has been shown to prolong
      remissions and survival in patients with relapsed indolent B-cell lymphomas. This trial is
      designed to show that higher dose rituximab plus maintenance rituximab can achieve similarly
      good results to chemotherapy approaches, but without chemotherapy-related toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  All participants will receive increased-dose rituximab through a vein in the arm once a
           week for 4 weeks (on Days 1, 8, 15, and 22 of the initial 28-day study cycle). This
           first cycle of study treatment is called the Induction Phase. If the participant
           responds well to the Induction Phase, they then may continue to the Maintenance Therapy
           Phase, where they will receive a lower dose of rituximab once every three months for up
           to 2 years.

        -  During the Induction Phase, the following procedures will take place before the
           participant receives each dose of rituximab: medical review, physical exam, performance
           status, and ECG. Blood tests will be drawn about 30-60 minutes after the first dose of
           rituximab on Day 1. Samples will be drawn immediately before each dose and again 30-60
           minutes after each dose on Days 1, 8, 15 and 22.

        -  During the Maintenance Therapy Phase, the following procedures will take place before
           the participant receives each dose of rituximab: medical review, physical exam,
           performance status, ECG, blood tests and response assessments by CT scan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Complete Response Rate (CRR) of Increased Dose Rituximab in Indolent B-cell Lymphomas</measure>
    <time_frame>after a median number of 8 maintenance cycles, up to 24 weeks</time_frame>
    <description>CR requires all of the following:
Regression to normal size on CT (≤ 1.5 cm in their greatest transverse diameter for nodes ≥ 1.5 cm before therapy). Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter before treatment must have decreased to &lt;1 cm in their greatest transverse diameter after treatment, or by more than 75% in the sum of the products of the greatest diameters (SPD).
The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination.
If bone marrow is known to be involved at the beginning, then repeat biopsy documents clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>after a median number of 8 maintenance cycles, up to 24 weeks</time_frame>
    <description>Complete Response (CR): see definition in primary outcome
Partial Response (PR):
≥50% decrease in SPD of up to 6 largest dominant masses
No new sites of disease or increase in the size of the other nodes, liver, or spleen.
Splenic and hepatic nodules must regress by at least 50% in the SPD.
Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Progressive Disease (PD) or Relapsed Disease (RD):
Appearance of a new lesion(s) &gt; 1.5 cm in any axis, ≥ 50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node &gt; 1 cm in short axis.
&gt;50% increase from nadir in the SPD of any previous lesions PFS is number of participants who have not died or had PD or RD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severity of Infusion Reactions, Infections and Neutropenia</measure>
    <time_frame>24 months</time_frame>
    <description>Toxicity grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>B-cell Lymphoma</condition>
  <condition>Indolent B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single-arm, open-label, interventional</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indolent B-Cell NHL of the following histologies:

               1. Follicular lymphoma (grades 1-3A);

               2. marginal zone lymphoma (extranodal, nodal or splenic):

                    -  Extranodal marginal zone lymphomas (MALT lymphomas) may not be candidates
                       for cure with antibiotics or local radiotherapy. Patients who have failed
                       antibiotics or local therapy are eligible for the protocol as long as they
                       have measurable disease and are naive to chemotherapy and monoclonal
                       antibody;

                    -  splenic marginal zone lymphoma patients may have received prior splenectomy
                       as long as they have measureable disease and are naive to chemotherapy and
                       monoclonal antibody therapy;

               3. Small lymphocytic lymphoma (must have less than 5000 circulating clonal
                  B-lymphocytes);

               4. Indolent CD20+ B-cell lymphoma not otherwise specified with CD20+ expression

          -  Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded) as 20mm or greater with
             conventional techniques or as 10mm or greater with spiral CT scan

          -  No previous chemotherapy, antibody therapy or radioimmunotherapy for NHL. Patients
             previously treated with external bean radiation alone, surgery, or with antibiotics
             are eligible

          -  18 years of age or older

          -  Life expectancy of greater than 3 months

          -  ECOG performance status of 2 or less

          -  Adequate bone marrow function

          -  Use of adequate contraception

        Exclusion Criteria:

          -  Prior chemotherapy, monoclonal antibody therapy or radioimmunotherapy for lymphoma

          -  Receiving any other investigational agent

          -  Known brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to rituximab

          -  HIV positivity

          -  Active hepatitis B infection

          -  Candidate for curative radiotherapy, unless radiation therapy is considered too toxic
             (as in abdominal disease), or is refused by the patient

          -  NYHA Classification III or IV disease

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection that is not optimally treated with antibiotics, unstable angina pectoris, or
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Pregnant women

          -  Individuals with a history of a different malignancy except for the following
             circumstances:

               1. disease-free for at least 1 year and are deemed by the investigator to be at low
                  risk for recurrence of that malignancy;

               2. localized prostate cancer, prostate cancer with elevated PSA but no measurable
                  disease on CT scans or bone scan, cervical cancer in situ; and

               3. non-melanoma skin cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Abramson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <results_first_submitted>March 29, 2017</results_first_submitted>
  <results_first_submitted_qc>March 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2017</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jeremy Abramson, MD</investigator_full_name>
    <investigator_title>Director, Lymphoma Program</investigator_title>
  </responsible_party>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rituximab</title>
          <description>single-arm, open-label, interventional
rituximab: Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>reason unknown</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab</title>
          <description>single-arm, open-label, interventional
rituximab: Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="36" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymphoma type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Follicular</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Marginal zone</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Small lymphocytic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indolent B cell, not otherwise specified</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Involvement of &gt;4 nodal sites</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hgb&lt;12 g/dL</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>elevated LDH (Lactate dehydrogenase)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follicular lymphoma prognostic index (FLIPI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Low risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intermediate risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FLIPI score not available</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Complete Response Rate (CRR) of Increased Dose Rituximab in Indolent B-cell Lymphomas</title>
        <description>CR requires all of the following:
Regression to normal size on CT (≤ 1.5 cm in their greatest transverse diameter for nodes ≥ 1.5 cm before therapy). Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter before treatment must have decreased to &lt;1 cm in their greatest transverse diameter after treatment, or by more than 75% in the sum of the products of the greatest diameters (SPD).
The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination.
If bone marrow is known to be involved at the beginning, then repeat biopsy documents clearance</description>
        <time_frame>after a median number of 8 maintenance cycles, up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>single-arm, open-label, interventional
rituximab: Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Complete Response Rate (CRR) of Increased Dose Rituximab in Indolent B-cell Lymphomas</title>
          <description>CR requires all of the following:
Regression to normal size on CT (≤ 1.5 cm in their greatest transverse diameter for nodes ≥ 1.5 cm before therapy). Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter before treatment must have decreased to &lt;1 cm in their greatest transverse diameter after treatment, or by more than 75% in the sum of the products of the greatest diameters (SPD).
The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination.
If bone marrow is known to be involved at the beginning, then repeat biopsy documents clearance</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Complete Response (CR): see definition in primary outcome
Partial Response (PR):
≥50% decrease in SPD of up to 6 largest dominant masses
No new sites of disease or increase in the size of the other nodes, liver, or spleen.
Splenic and hepatic nodules must regress by at least 50% in the SPD.
Overall Response (OR) = CR + PR.</description>
        <time_frame>after a median number of 8 maintenance cycles, up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>single-arm, open-label, interventional
rituximab: Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Complete Response (CR): see definition in primary outcome
Partial Response (PR):
≥50% decrease in SPD of up to 6 largest dominant masses
No new sites of disease or increase in the size of the other nodes, liver, or spleen.
Splenic and hepatic nodules must regress by at least 50% in the SPD.
Overall Response (OR) = CR + PR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progressive Disease (PD) or Relapsed Disease (RD):
Appearance of a new lesion(s) &gt; 1.5 cm in any axis, ≥ 50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node &gt; 1 cm in short axis.
&gt;50% increase from nadir in the SPD of any previous lesions PFS is number of participants who have not died or had PD or RD.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>single-arm, open-label, interventional
rituximab: Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progressive Disease (PD) or Relapsed Disease (RD):
Appearance of a new lesion(s) &gt; 1.5 cm in any axis, ≥ 50% increase in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node &gt; 1 cm in short axis.
&gt;50% increase from nadir in the SPD of any previous lesions PFS is number of participants who have not died or had PD or RD.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Severity of Infusion Reactions, Infections and Neutropenia</title>
        <description>Toxicity grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>single-arm, open-label, interventional
rituximab: Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Severity of Infusion Reactions, Infections and Neutropenia</title>
          <description>Toxicity grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3/4 neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any allergic reactions with infusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 allergic reactions with infusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rituximab</title>
          <description>single-arm, open-label, interventional
rituximab: Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <description>grade 4, unexpected and unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis (toe)</sub_title>
                <description>grade 3, expected and possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>grade 3, unexpected and possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <description>grade 3, unexpected and unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="495" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="38" subjects_affected="13" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="32" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema head and neck</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hematologic-other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing-other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Otitis- middle ear (non-infectious)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyopthyroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular-other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" events="32" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="97" subjects_affected="24" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdomen- pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" events="20" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Back-pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pelvic-pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Joint-pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Extremity-limb- pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neck- pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest/thoracic pain NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muscle- pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest wall- pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="493" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="8" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" events="493" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- upper airway</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- bronchus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- sinus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- urinary tract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut- lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="493" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="14" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>AST- SGOT</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ALT- SGPT</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory-other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="21" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="18" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="18" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="34" subjects_affected="15" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Bronchospasm- wheezing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeremy Abramson, MD</name_or_title>
      <organization>Massachusetts General Hospital Cancer Center</organization>
      <phone>617-724-4000</phone>
      <email>jabramson@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

